Cargando…

Orthobiologic Injections for the Treatment of Hip Osteoarthritis: A Systematic Review

The use of orthobiologics is gaining increasing interest as a minimally invasive treatment for hip osteoarthritis (OA). The aim of this study was to investigate the evidence about the safety and efficacy of these products. A systematic review of the literature was performed according to the PRISMA a...

Descripción completa

Detalles Bibliográficos
Autores principales: Zaffagnini, Marco, Boffa, Angelo, Andriolo, Luca, Raggi, Federico, Zaffagnini, Stefano, Filardo, Giuseppe
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9699182/
https://www.ncbi.nlm.nih.gov/pubmed/36431138
http://dx.doi.org/10.3390/jcm11226663
_version_ 1784839008359022592
author Zaffagnini, Marco
Boffa, Angelo
Andriolo, Luca
Raggi, Federico
Zaffagnini, Stefano
Filardo, Giuseppe
author_facet Zaffagnini, Marco
Boffa, Angelo
Andriolo, Luca
Raggi, Federico
Zaffagnini, Stefano
Filardo, Giuseppe
author_sort Zaffagnini, Marco
collection PubMed
description The use of orthobiologics is gaining increasing interest as a minimally invasive treatment for hip osteoarthritis (OA). The aim of this study was to investigate the evidence about the safety and efficacy of these products. A systematic review of the literature was performed according to the PRISMA and Cochrane guidelines. The study quality was assessed using the RoB 2.0 for randomized controlled trials (RCTs) and the modified Coleman Methodology Score (mCMS) for all studies. A total of 20 clinical studies (735 patients) was identified, 12 on PRP injections and eight on cell-based therapies (five from bone marrow, two from adipose tissue, and one from amniotic fluid). The publication trend increased over time, with over 50% of articles published from 2019. The literature analysis showed only six RCTs, all on PRP injections. The mCMS showed an overall fair methodology (mean score 59.4). While the number of studies and their methodology are still limited, the available evidence suggests safety and overall promising results, with the treatment success being inversely proportional to the severity of OA. Further high-level controlled trials are needed before drawing more definitive conclusions on the real potential of orthobiologics for the injective treatment of patients affected by hip OA.
format Online
Article
Text
id pubmed-9699182
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher MDPI
record_format MEDLINE/PubMed
spelling pubmed-96991822022-11-26 Orthobiologic Injections for the Treatment of Hip Osteoarthritis: A Systematic Review Zaffagnini, Marco Boffa, Angelo Andriolo, Luca Raggi, Federico Zaffagnini, Stefano Filardo, Giuseppe J Clin Med Review The use of orthobiologics is gaining increasing interest as a minimally invasive treatment for hip osteoarthritis (OA). The aim of this study was to investigate the evidence about the safety and efficacy of these products. A systematic review of the literature was performed according to the PRISMA and Cochrane guidelines. The study quality was assessed using the RoB 2.0 for randomized controlled trials (RCTs) and the modified Coleman Methodology Score (mCMS) for all studies. A total of 20 clinical studies (735 patients) was identified, 12 on PRP injections and eight on cell-based therapies (five from bone marrow, two from adipose tissue, and one from amniotic fluid). The publication trend increased over time, with over 50% of articles published from 2019. The literature analysis showed only six RCTs, all on PRP injections. The mCMS showed an overall fair methodology (mean score 59.4). While the number of studies and their methodology are still limited, the available evidence suggests safety and overall promising results, with the treatment success being inversely proportional to the severity of OA. Further high-level controlled trials are needed before drawing more definitive conclusions on the real potential of orthobiologics for the injective treatment of patients affected by hip OA. MDPI 2022-11-10 /pmc/articles/PMC9699182/ /pubmed/36431138 http://dx.doi.org/10.3390/jcm11226663 Text en © 2022 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
spellingShingle Review
Zaffagnini, Marco
Boffa, Angelo
Andriolo, Luca
Raggi, Federico
Zaffagnini, Stefano
Filardo, Giuseppe
Orthobiologic Injections for the Treatment of Hip Osteoarthritis: A Systematic Review
title Orthobiologic Injections for the Treatment of Hip Osteoarthritis: A Systematic Review
title_full Orthobiologic Injections for the Treatment of Hip Osteoarthritis: A Systematic Review
title_fullStr Orthobiologic Injections for the Treatment of Hip Osteoarthritis: A Systematic Review
title_full_unstemmed Orthobiologic Injections for the Treatment of Hip Osteoarthritis: A Systematic Review
title_short Orthobiologic Injections for the Treatment of Hip Osteoarthritis: A Systematic Review
title_sort orthobiologic injections for the treatment of hip osteoarthritis: a systematic review
topic Review
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9699182/
https://www.ncbi.nlm.nih.gov/pubmed/36431138
http://dx.doi.org/10.3390/jcm11226663
work_keys_str_mv AT zaffagninimarco orthobiologicinjectionsforthetreatmentofhiposteoarthritisasystematicreview
AT boffaangelo orthobiologicinjectionsforthetreatmentofhiposteoarthritisasystematicreview
AT andriololuca orthobiologicinjectionsforthetreatmentofhiposteoarthritisasystematicreview
AT raggifederico orthobiologicinjectionsforthetreatmentofhiposteoarthritisasystematicreview
AT zaffagninistefano orthobiologicinjectionsforthetreatmentofhiposteoarthritisasystematicreview
AT filardogiuseppe orthobiologicinjectionsforthetreatmentofhiposteoarthritisasystematicreview